MX2020013557A - Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. - Google Patents
Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.Info
- Publication number
- MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disubstituted
- pyrazolyl steroid
- subject
- compound
- Prior art date
Links
- 201000009916 Postpartum depression Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013557A true MX2020013557A (es) | 2021-05-27 |
Family
ID=67211854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013557A MX2020013557A (es) | 2018-06-12 | 2019-06-12 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. |
| MX2025000166A MX2025000166A (es) | 2018-06-12 | 2020-12-11 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025000166A MX2025000166A (es) | 2018-06-12 | 2020-12-11 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20210338692A1 (https=) |
| EP (1) | EP3806863A1 (https=) |
| JP (3) | JP2021527092A (https=) |
| KR (1) | KR20210021005A (https=) |
| CN (2) | CN112533611A (https=) |
| AU (2) | AU2019287491B2 (https=) |
| CA (1) | CA3103421A1 (https=) |
| IL (1) | IL279315A (https=) |
| MA (1) | MA52894A (https=) |
| MX (2) | MX2020013557A (https=) |
| SG (1) | SG11202012344RA (https=) |
| WO (1) | WO2019241442A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| KR20220112803A (ko) * | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| KR20230041049A (ko) * | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| KR20230136599A (ko) * | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| US20240245711A1 (en) * | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| WO2022232504A1 (en) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| EP4329769A1 (en) * | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL315023A (en) * | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| KR20240157128A (ko) * | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| EP3504189A1 (en) * | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
-
2019
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko active Pending
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en not_active Ceased
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491B2/en active Active
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
- 2020-12-11 MX MX2025000166A patent/MX2025000166A/es unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en not_active Abandoned
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
-
2024
- 2024-12-12 US US18/978,431 patent/US20250339447A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064902A patent/JP2025108553A/ja active Pending
- 2025-08-15 AU AU2025217363A patent/AU2025217363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112533611A (zh) | 2021-03-19 |
| JP2024028849A (ja) | 2024-03-05 |
| CN117959309A (zh) | 2024-05-03 |
| JP2025108553A (ja) | 2025-07-23 |
| MX2025000166A (es) | 2025-03-07 |
| AU2019287491B2 (en) | 2025-05-15 |
| IL279315A (en) | 2021-01-31 |
| US20210338692A1 (en) | 2021-11-04 |
| KR20210021005A (ko) | 2021-02-24 |
| US20250339447A1 (en) | 2025-11-06 |
| WO2019241442A1 (en) | 2019-12-19 |
| MA52894A (fr) | 2021-04-21 |
| JP2021527092A (ja) | 2021-10-11 |
| TW202005653A (zh) | 2020-02-01 |
| EP3806863A1 (en) | 2021-04-21 |
| SG11202012344RA (en) | 2021-01-28 |
| CA3103421A1 (en) | 2019-12-19 |
| US20200113917A1 (en) | 2020-04-16 |
| AU2025217363A1 (en) | 2025-09-04 |
| AU2019287491A1 (en) | 2021-01-07 |
| US20220323462A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2023010063A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
| MX2023012727A (es) | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. | |
| WO2019200314A3 (en) | Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof | |
| MX2019008999A (es) | Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| PH12022551468A1 (en) | Compounds active towards nuclear receptors | |
| MX2021010989A (es) | Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2021006933A (es) | Administración de sulcardina para el tratamiento de fibrilación auricular aguda. |